# Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio

> **NCT06732804** · PHASE1 · COMPLETED · sponsor: **Alvotech Swiss AG** · enrollment: 385 (actual)

## Conditions studied

- Healthy Male and Female Subjects

## Interventions

- **BIOLOGICAL:** AVT80
- **BIOLOGICAL:** Geographical region 1 Entyvio
- **BIOLOGICAL:** Geographical region 2 Entyvio

## Key facts

- **NCT ID:** NCT06732804
- **Lead sponsor:** Alvotech Swiss AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-11
- **Primary completion:** 2026-01-08
- **Final completion:** 2026-01-08
- **Target enrollment:** 385 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06732804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06732804, "Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06732804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*